welcome
About us
Newsletter
News Widget
Media Inquiries

Summary

Canine Cancer Drug Fast-Track

This is a US news story, published by New Atlas, that relates primarily to OST-HER2 news.

US news

For more US news, you can click here:

more US news

pets, animals & wildlife news

For more pets, animals & wildlife news, you can click here:

more pets, animals & wildlife news

New Atlas news

For more news from New Atlas, you can click here:

more news from New Atlas

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best entertainment news, business news, world news, and much more. If you like pets, animals & wildlife news, you might also like this article about

canine osteosarcoma

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest common canine cancer news, deadly canine cancer news, pets, animals & wildlife news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

shelf canine osteosarcoma treatment
New Atlas

New Atlas

•

Entertainment

Entertainment

Canine cancer drug fast-tracked for treating kids

New Atlas
Summary
Nutrition label

85% Informative

Comparative oncology is the study of naturally occurring cancers in companion animals, such as dogs and cats, as models for the treatment of human disease.

OST-HER2 is the most common canine cancer, affecting more than 40,000 dogs in the US each year .

The drug was featured in a recent PBS documentary, Shelter Me: The Cancer Pioneers.

OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration .

OST intends to submit a Biologics License Application (BLA) to the FDA this year .

OS Therapies is laser-focused on getting an Accelerated Approval in recurrent, fully resected, lung metastatic human osteosarcoma by year-end 2025 .

VR Score

83

Informative language

83

Neutral language

28

Article tone

formal

Language

English

Language complexity

69

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

long-living

External references

20

https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-trackhttps://ir.ostherapies.com/news-events/press-releases/detail/57/os-therapies-announces-positive-data-for-ost-her2-in-thehttps://ccr.cancer.gov/comparative-oncology-programhttps://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-programhttps://ir.ostherapies.com/news-events/press-releases/detail/41/os-therapies-announces-phase-2b-clinical-trial-of-ost-her2https://ir.ostherapies.com/news-events/press-releases/detail/61/os-therapies-forms-subsidiary-os-animal-health-tohttps://www.ncbi.nlm.nih.gov/books/NBK534838/https://www.pbs.org/video/the-cancer-pioneers-jemhoc/https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cberhttps://www.ema.europa.eu/en/human-regulatory-overview/paediatric-medicines-overview#paediatric-medicines-in-the-product-lifecycle-11187https://creativecommons.org/licenses/by-sa/4.0/deed.enhttps://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programshttps://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-productshttps://ostherapies.com/profile/paul-romness/https://ostherapies.com/profile/robert-petit/https://healthtopics.vetmed.ucdavis.edu/health-topics/canine/appendicular-osteosarcoma-dogshttps://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(25)00113-3https://ir.ostherapies.com/news-events/press-releases/detail/60/os-therapies-announces-issuance-of-u-s-patent-12239738https://clinicaltrials.gov/study/NCT04974008https://ostherapies.com/

Source diversity

11

www.fda.govir.ostherapies.comccr.cancer.govwww.ncbi.nlm.nih.govwww.pbs.orgwww.ema.europa.eucreativecommons.orgostherapies.comhealthtopics.vetmed.ucdavis.eduwww.cell.comclinicaltrials.gov

Affiliate links

no affiliate links

Read full article